SGLT2 Inhibitors (e.g., Dapagliflozin)
Treatment for Chronic kidney disease due to hypertension
Effectiveness
95%
Safety Score
65%
Clinical Trials
30
Participants
50K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
0
SGLT2 Inhibitors (e.g., Dapagliflozin) Outcomes
for Chronic kidney disease due to hypertension
Efficacy Outcomes
Overall Effectiveness
+95%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov